The global onchocerciasis treatment market is primarily driven by the widespread prevalence of onchocerciasis in sub-Saharan Africa, where over 20 million people are infected, and approximately 125 million are at risk. The disease, transmitted by the blackfly, causes significant public health issues, including blindness, affecting about 1 million people globally. Treatment efforts are led by mass drug administration (MDA) programs, primarily using ivermectin, with emerging alternatives such as moxidectin showing promising results. The market is influenced by the involvement of international organizations and governments, which provide free or subsidized treatments, particularly in low-income countries. Despite progress in controlling the disease, challenges such as reaching remote populations and ensuring adherence to treatment regimens persist. Ongoing research aims to improve treatment efficacy, with new drugs and delivery mechanisms potentially enhancing disease control efforts.
